Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DTacP Vaccine in Children Aged 2 Months to 6 Years
NCT06184542Phase 1Recruiting
- Sponsor
- Institute of Medical Biology
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of diphtheria + tetanus + acellular pertussis vaccine in diphtheria, Tetanus and pertussis (11 arms), sponsored by Institute of Medical Biology. Primary endpoints: Incidence of adverse events within 30 minutes after vaccination, Incidence of solicited adverse events within 7 days after vaccination and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
diphtheria + tetanus + acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT06184542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184542.